Hans-PeterKiemMD

PubMed

• andexpansion of CD33/HBG promoter-edited HSPCs with Mylotarg.
  Aphrodite Georgakopoulou, Chang Li, Hans-Peter Kiem, André Lieber
  Molecular Therapy. Methods & Clinical Development. 2024-12-12
• Introducing a hemoglobin G-Makassar variant in HSCs by in vivo base editing treats sickle cell disease in mice.
  Chang Li, Aphrodite Georgakopoulou, Kiriaki Paschoudi, Anna K Anderson, Lishan Huang
  Molecular Therapy. 2024-12-04
• 2 citations
  Targeting the membrane-proximal C2-set domain of CD33 for improved CAR T cell therapy.
  Salvatore Fiorenza, Sheryl Y T Lim, George S Laszlo, Erik L Kimble, Tinh-Doan Phi
  Molecular Therapy. Oncology. 2024-09-19

Abstracts/Posters

• Fully Closed, Large-Scale, and Clinical Grade Cell Sorting of Hematopoietic Stem Cell (HSC)-Enriched CD90+ Cells for Transplantation and Gene Therapy
  Hans-Peter Kiem, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival after Repeat Infusions of CD19 CAR-T CellsClinically Relevant Abstract
  Hans-Peter Kiem, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical Outcomes
  Hans-Peter Kiem, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• CRISPR/Cas9-Mediated Protection of Normal Hematopoiesis Combined with the CD33/CD3 Bispecific T-Cell Engager (BiTE) Antibody AMG330 for Improved AML Therapy
  Hans-Peter Kiem, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Non-Genotoxic Conditioning Efficiently Depletes Host Hematopoietic Stem Cells and Facilitates Robust Multi-Lineage Engraftment in a Mouse Model of Fanconi Anemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Engineering Resistance to CD33-Targeted Immunotherapy in Normal Hematopoiesis By CRISPR/Cas9-Deletion of CD33 Exon 2 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• From Bone Marrow to Mobilized Peripheral Blood Stem Cells: The Circuitous Path to Clinical Gene Therapy for Fanconi AnemiaClinically Relevant Abstract 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Immunotherapy with T-Cells Engineered with a Chimeric Antigen Receptor Bearing a Human CD19-Binding Single Chain Variable Fragment for Relapsed or Refractory Acute Lym... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all